Literature DB >> 2571966

Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon.

J D'Emilia1, K Bulovas, K D'Ercole, B Wolf, G Steele, I C Summerhayes.   

Abstract

The c-erbB-2 gene has been found amplified in a number of human adenocarcinomas leading to elevated levels of expression of the p185 protein product. Increased expression of this putative growth factor receptor has been reported to occur by molecular mechanism other than gene amplification and for this reason we have studied the expression of the p185 protein in normal colon and in lesions representing different stages of neoplastic progression. We report amplification of the c-erbB-2 gene in 3 of 44 colon carcinomas and 1 of 5 preneoplastic polyps studied. Confirmation of expression of the p185 protein product was established in Western blot analysis and by immunocytochemical staining of tissue sections. An extended study, involving adenomatous polyps and carcinomatous material in immunostaining, revealed detectable presence of the p185 protein in 20% of carcinomas, consistent with immunoprecipitation data derived using established cell lines. In contrast, a high percentage of polyps showed strong staining with both p185 antibodies used, indicating elevated levels of expression of the c-erbB-2 protein associated with preneoplastic lesions. Staining of normal human colon revealed a restricted localization of this putative receptor to cells on the luminal colonic surface, with no expression in cells of the crypt. Histologically normal mucosa, adjacent to the tumor, showed a more extensive distribution involving the crypt suggestive of a disturbance in the normal expression of c-erbB-2. These results indicate that elevated expression of the c-erbB-2 protein is associated with early stages of colonic neoplasia but do not establish it as a primary factor in these events. The occurrence of multiple copies of the c-erbB-2 in a percentage of colon lesions, however, suggests a possible role for this gene in some colon malignancies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571966

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Authors:  Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Int J Colorectal Dis       Date:  2006-09-01       Impact factor: 2.571

Review 2.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

3.  Structural and functional aspects of the multiplicity of Neu differentiation factors.

Authors:  D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

4.  Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.

Authors:  Jayson Wang; James Hollingshead; Nabil El-Masry; Donna Horncastle; Ian Talbot; Ian Tomlinson; Malcolm R Alison; Mona El-Bahrawy
Journal:  J Gastrointest Cancer       Date:  2012-09

5.  Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.

Authors:  Hirofumi Asakura; Hitoshi Takashima; Masahiro Mitani; Reiji Haba; Reiko Seo; Koiku Yokoe; Yoshihiro Toyama; Motoomi Ohkawa
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

6.  SSO Clinical Award Lecture. The surgical oncologist as a key translator of basic biology to patients with gastrointestinal cancer: asking the right questions.

Authors:  G Steele
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

7.  The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines.

Authors:  Kaifee Arman; Sercan Ergün; Ebru Temiz; Serdar Öztuzcu
Journal:  Mol Biol Rep       Date:  2014-09-05       Impact factor: 2.316

8.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

9.  HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

Authors:  A H Arnaout; P M Dawson; S Soomro; P Taylor; N A Theodorou; M Feldmann; B M Fendly; H M Shepard; S Shousha
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

10.  Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.

Authors:  L Bangalore; A J Tanner; A P Laudano; D F Stern
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.